Ikarian Capital’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-21,161
Closed -$65.2K 191
2025
Q4
$65.2K Hold
21,161
0.01% 165
2025
Q3
$139K Hold
21,161
0.01% 158
2025
Q2
$190K Sell
21,161
-2
-0% -$17 0.04% 114
2025
Q1
$134K Hold
21,163
0.02% 147
2024
Q4
$218K Buy
21,163
+26
+0.1% +$286 0.03% 150
2024
Q3
$272K Hold
21,137
0.04% 131
2024
Q2
$292K Hold
21,137
0.05% 103
2024
Q1
$6.57M Sell
21,137
-3,951
-16% -$1.05M 0.72% 45
2023
Q4
$6.57M Hold
25,088
0.62% 55
2023
Q3
$4.9M Buy
25,088
+5,515
+28% +$987K 0.59% 50
2023
Q2
$4.02M Buy
19,573
+12,699
+185% +$1.76M 0.64% 47
2023
Q1
$711K Hold
6,874
0.16% 88
2022
Q4
$1.08M Hold
6,874
0.26% 48
2022
Q3
$1.72M Sell
6,874
-73
-1% -$21.6K 0.34% 59
2022
Q2
$1.96M Sell
6,947
-1,500
-18% -$408K 0.36% 58
2022
Q1
$1.7M Buy
8,447
+556
+7% +$122K 0.22% 75
2021
Q4
$1.72M Sell
7,891
-178
-2% -$57.2K 0.26% 72
2021
Q3
$3.69M Sell
8,069
-4,425
-35% -$1.67M 0.26% 85
2021
Q2
$5.02M Sell
12,494
-3,121
-20% -$1.42M 0.41% 69
2021
Q1
$9.05M Sell
15,615
-692
-4% -$432K 0.3% 75
2020
Q4
$9.29M Buy
16,307
+8,548
+110% +$4.82M 0.41% 58
2020
Q3
$4.34M Buy
+7,759
New +$4.82M 0.31% 73

Other funds holding LYRA

Ikarian Capital's LYRA Position: Q1 2026 in Review

Ikarian Capital sold out of LYRA THERAPEUTICS INC (LYRA) in Q1 2026, closing a stake of 21,161 shares — an estimated $65.2K sold.

Ikarian Capital first reported a position in LYRA in Q3 2020 and held it in 22 quarters. The position peaked at $9.29M in Q4 2020. 1 fund tracked by Wall St. Rank holds LYRA as of Q1 2026.

  • Ikarian Capital reported no remaining LYRA THERAPEUTICS INC position as of Q1 2026 after selling out during the quarter.
  • Ikarian Capital sold 21,161 LYRA THERAPEUTICS INC shares in Q1 2026, an estimated $65.2K.
  • Ikarian Capital first reported a position in LYRA THERAPEUTICS INC in Q3 2020 and held it in 22 quarters.
  • Ikarian Capital's LYRA THERAPEUTICS INC position peaked at $9.29M in Q4 2020.
  • 1 fund tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.